Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Change in Inventory (2016 - 2025)

Protalix BioTherapeutics has reported Change in Inventory over the past 16 years, most recently at $4.5 million for Q4 2025.

  • Quarterly results put Change in Inventory at $4.5 million for Q4 2025, up 10.63% from a year ago — trailing twelve months through Dec 2025 was $4.5 million (up 104.09% YoY), and the annual figure for FY2025 was $4.5 million, up 104.09%.
  • Change in Inventory for Q4 2025 was $4.5 million at Protalix BioTherapeutics, up from $124000.0 in the prior quarter.
  • Over the last five years, Change in Inventory for PLX hit a ceiling of $4.5 million in Q4 2025 and a floor of -$3.5 million in Q3 2024.
  • Median Change in Inventory over the past 5 years was $478500.0 (2021), compared with a mean of $632350.0.
  • Biggest five-year swings in Change in Inventory: surged 1720.1% in 2021 and later tumbled 667.82% in 2023.
  • Protalix BioTherapeutics' Change in Inventory stood at $3.2 million in 2021, then plummeted by 30.46% to $2.2 million in 2022, then plummeted by 213.2% to -$2.5 million in 2023, then surged by 259.34% to $4.0 million in 2024, then rose by 10.63% to $4.5 million in 2025.
  • The last three reported values for Change in Inventory were $4.5 million (Q4 2025), $124000.0 (Q3 2025), and $1.6 million (Q2 2025) per Business Quant data.